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Abstract
The inaccuracy of 17-β estradiol (E2) measurements affects its use as a biomarker in patient care 
and research. Clinical and research communities called for accurate and standardized E2 
measurements. Reference Measurement Procedures (RMPs), part of the CDC Hormone 
Standardization Program (HoSt), are essential in addressing this need and ensuring that methods 
are accurate and comparable across testing systems, laboratories, and over time. A candidate RMP 
(cRMP) was developed for the measurement of total E2 in serum using liquid chromatography-
tandem mass spectrometry (LC-MS/MS) without derivatization. The cRMP meets suggested 
performance criteria for accuracy and precision through the use of isotope dilution, calibrator 
bracketing, and gravimetric measurements. The cRMP demonstrated high agreement with certified 
reference materials (no significant bias to BCR576, 577, and 578) and established RMPs (slope 
1.00, 95% CI 1.00–1.01; intercept 0.02, 95% CI -0.01 to 0.06). The cRMP is highly precise with 
intra-assay, interassay, and total percent CVs of 2.7%, 1.3%, and 2.4%, respectively. A higher 
specificity was achieved by measuring E2 without derivatization, compared to methods using 
derivatization agents. The cRMP can serve as a higher-order standard for establishing 
measurement traceability and provides an accuracy base against which routine methods can be 
compared in HoSt.
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Estradiol (E2) measurements are used to monitor antiestrogen therapy (e.g., aromatase 
inhibitor therapy),1 assess fertility,2 monitor sex steroid metabolism disorders,3 identify E2 
secreting tumors,4 and assess fracture risk.5 Several research studies and meta-analyses 
found that elevated E2 levels in postmenopausal women increase the risk for breast cancer 
with relative risk ratios similar to those observed for cholesterol levels and cardiovascular 
disease risk.6,7 Additional studies have reported associations between E2 and the risk of 
endometrial cancer,8,9 cardiovascular disease,10 and cognitive function.11
E2 measurements are reported to be inaccurate and highly variable, especially at the low 
concentrations observed in men, postmenopausal women, and women on aromatase inhibitor 
therapy.1,12–14 It has been suggested that the source of high variability at low concentrations 
is due to lack of method specificity,1,12,13,15 which can impact the diagnosis and treatment 
assessments of patients. For example, it has been suggested that in postmenopausal women 
on aromatase inhibitor therapy, inaccurate measurements can lead to incorrect assessments 
of treatment efficacy.15–17
A recent report from the clinical and research community and a position statement by The 
Endocrine Society recognized the problem with inaccurate E2 measurements and the need to 
improve steroid hormones measurements.1,12 To make improvements, clinical laboratories, 
proficiency testing (PT) providers, and assay manufacturers need access to highly accurate 
and precise reference measurement procedures (RMPs) to assess the trueness of analytical 
methods used in patient care and research. To address these needs, the CDC established the 
Hormone Standardization Program (HoSt).18,19 One key component of this program is an 
RMP for E2.
RMPs are analytically involved, are laborious, require larger sample volumes, and as a result 
are not practical for routine laboratories to adopt. Only three RMPs for E2 in serum are 
recognized by the Joint Committee for Traceability in Laboratory Medicine (JCTLM) as 
meeting criteria for higher-order reference method standards according to ISO 15193.20,21 
Two of the methods use gas chromatography/mass spectrometry (GC/MS)22,23 and one uses 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology.24 The new 
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proposed candidate RMP (cRMP) meets the accuracy and precision recommendations for 
measuring E2 with sufficient sensitivity for assigning target values in serum of men and 
women (pre- and postmenopausal) and is comparable to established RMPs. In contrast to the 
published LC-MS/MS RMP, this method uses optimized chromatography without requiring 
derivatization to improve specificity. In addition, no operational RMP exists in the United 
States to address the needs of the clinical laboratories, PT providers, and assay 
manufacturers. The cRMP presented here is suitable to meet these needs.
MATERIALS AND METHODS
Certified primary reference standard for 17-β estradiol NMIJ CRM 6004-a lot 009 from 
National Metrology Institute of Japan (Ibaraki, Japan) with a purity of 98.4% was used as 
calibrators. [2H5]-estradiol lot B0369 (Steraloids, Newport, RI), with an isotopic purity of 
99.0%, was used as an internal standard (IS). HPLC-grade methanol and hexane, as well as 
reagent-grade ammonium carbonate and sodium acetate were obtained from Fisher 
Scientific (Suwanee, GA). Anhydrous ethanol was purchased from Sigma-Aldrich (St. 
Louis, MO). Ammonium fluoride was obtained from Acros (Pittsburgh, PA). Steroids 
analyzed for interference testing (Table 1) were obtained from Steraloids (Newport, RI), 
LGC Standards (Manchester, NH), Cerilliant (Round Rock, TX) and Sigma-Aldrich (St. 
Louis, MO). Three levels of serum-based certified reference materials (BCR 576, BCR 577, 
and BCR 578) were purchased from the Institute for Reference Materials and Measurements 
(IRMM, Geel, Belgium). Fresh-frozen, single-donor serum materials were obtained from 
Solomon Park Research Laboratories (Kirkland, WA). Other serum materials for QC 
preparation and matrix evaluations were obtained from BioreclamationIVT (Westbury, NY).
Calibrator Preparation
All volumetric steps for the calibrator and sample preparation were controlled by 
gravimetric measurements. Mass fractions (mg/g) were calculated for all calibrator stock 
solutions and calibrators. For the purpose of this manuscript, mass fractions (mg/g) were 
converted into volume concentrations using the specific density determined with a DMA 500 
density meter (Anton Paar, Ashland, VA). A primary stock solution (PSS) was prepared by 
dissolving 300 mg of E2 in 100 mL of anhydrous ethanol and further diluting was achieved 
through addition of 200 μL of this solution in 100 mL of anhydrous ethanol (Stock B). Stock 
C was created by diluting 100 μL of Stock B solution in 100 mL of anhydrous ethanol. 
Three working standard solutions were prepared by diluting 5.0 mL, 1.0 mL, and 100 μL of 
Stock C in 100 mL of anhydrous ethanol: WS1 (1.10 nM [300 pg/mL]), WS2 (220 pM [60.0 
pg/mL]) and WS3 (22.0 pM [6.00 pg/ mL]). Internal standard (IS) PSS and working 
standard solutions ISWS1, ISWS2, and ISWS3 were prepared using [2H5]-estradiol in the 
same manner as unlabeled E2 to obtain similar final concentrations. WS1 and ISWS1 (high) 
solutions were used to quantitate values typically reported in premenopausal women (>257 
pM [70.0 pg/mL]), WS2 and ISWS2 (medium) for men and some postmenopausal women 
(36.7–257 pM [10.0–70.0 pg/mL]), and WS3 and ISWS3 (low) for postmenopausal women 
(<36.7 pM [10.0 pg/mL]).
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Similar to procedures previously described, five point calibration curves were prepared by 
adding varying amounts of ISWS solution to WS solution to obtain mass ratios of unlabeled 
to labeled E2 of 0.5, 0.8, 1.0, 1.2, and 1.5.25,26 The procedure was applied to establish 
calibration curves for a concentration range of high 440–734 pM (120–200 pg/mL), medium 
88.1–147 pM (24.0–40.0 pg/mL), and low 8.81–14.7 pM (2.40–4.00 pg/mL). Calibration 
curves were prepared in triplicate.
Sample Preparation
Determination of E2 concentration in a sample was performed using bracketing calibration 
as described previously.25,26 In brief, the amount of ISWS solution was adjusted to achieve 
an approximate mass ratio of one to the endogenous E2. For that, a routine method measured 
the approximate concentration of E2 in the sample. The result from this measurement was 
used to determine the amount of ISWS solution needed to achieve the ratio of one. The 
ISWS solution was transferred to a glass vial, and the solvent was evaporated under vacuum 
prior to addition of serum to avoid protein precipitation. For analysis of high concentration 
samples, 0.5 mL of serum was used; for medium concentration samples 1.0 mL was used; 
and for low concentration samples 3.0–5.0 mL was used, depending upon the approximate 
concentration of the sample. The samples and IS were allowed to equilibrate at room 
temperature for 30 min while gently shaking as previously described to improve accuracy 
and reproducibility.22
E2 was released from binding proteins with the addition of sodium acetate (0.5 M, pH 5.5) 
at a sample-to-buffer ratio of 1:2 (v/v) and equilibrated at room temperature (20 °C) for 2 h. 
Liquid/liquid extraction (LLE) was performed in duplicate using 2.5 mL of an ethyl acetate-
hexane (3:2, v/v) solution. The two organic extracts were combined, evaporated to dryness 
under vacuum, and reconstituted in 0.5 mL of ammonium carbonate (0.2 M, pH 8.2). To 
remove polar lipids, the solution was extracted using 3 mL of ethyl acetate-hexane (3:2, v/v) 
in duplicate. The organic layers were dried under vacuum and reconstituted with 120 μL of a 
water-methanol mixture (80:20, v/v) for LC-MS/MS analysis. Three quality control (QC) 
materials from unaltered, pooled serum (QCLow, QCMedium, and QCHigh) and three 
IRMM certified reference materials (BCR 576, BCR 577, and BCR 578) were prepared by 
reconstitution according to the certificates of analysis and analyzed in duplicate in each run.
LC-MS/MS Conditions
Two injections for each preparation were performed on an AB/Sciex API 5500 tandem mass 
spectrometer (Foster City, CA) equipped with a Shimadzu LC-10AD/SIL-30AC Nexera 
system (Columbia, MD). A Phenyl/ Hexyl Kinetex, 50 mm × 4.6 mm, 2.6 μm analytical 
column with a guard column (Phenomenex, Torrance, CA) heated to 40 °C was used with 
0.2 mM ammonium fluoride in water (Buffer A) and methanol only (Buffer B). The HPLC 
separation was achieved with a 9 min gradient from 48% to 62% Buffer B at a flow rate of 
750 μL/min. The mass spectrometer was operated with electrospray ionization (ESI) in the 
negative ion mode with voltage set to −4 000 V, collision energy set to −50 eV, and Turbo 
Ion Spray Source temperature set at 650 °C. Selected reaction monitoring (SRM) was used 
with the following transitions: m/z 271 → 145 (quantitation ion, QI) and m/z 271 → 183 
(confirmation ion, CI) for E2 and with 276 → 147 (QI) and m/z 276 → 187 (CI) for the IS.
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Data Analysis
Analyst 1.6.2 software (AB/Sciex, Framingham, MA) was used to integrate selected peaks. 
Quantitation was performed with the peak area count ratio of the E2 QI to the IS QI. The 
mean area count ratios from the two injections were used for data analysis. To convert the 
mass fraction to the commonly used volume concentration, the density of the serum samples 
was used. For value assignment, duplicate preparations of serum were made in two 
independent runs (n = 4). The mean value from four measurements was used to assign an E2 
concentration to the sample. Statistical evaluations for Deming regression and difference 
plots were performed with Analyze-It Software, Ltd. version 2.26 (Leeds, U.K.) using t test, 
α = 0.05.
Method Validation
Accuracy was evaluated through a comparison with a JCTLM-recognized RMP at the 
University of Ghent (JCTLM code-NRMeth 10)23 and IRMM certified reference materials. 
The mean percent bias of the cRMP to the JCTLM-recognized RMP was determined 
following the CLSI document EP 9 A2 protocol comparing 40 single-donor serum 
samples.27 The cRMP was compared to the JCTLM-recognized RMP values using a 
Deming regression analysis. In addition, IRMM certified reference materials were analyzed, 
and the mean percent difference from the certified value was determined and evaluated for 
significance as described in NIST Special Publication 829.28
Imprecision was evaluated by analyzing 3 serum pools in duplicate over 5 days. CLSI EP 
10-A3 was used to calculate the intra-assay, interassay, and total percent coefficients of 
variation (CVs).29 Standard uncertainty and expanded uncertainty of the cRMP following 
the ISO Guide to the Expression of Uncertainty in Measurement 2008 was also evaluated.30 
The estimated variance of type A uncertainty was calculated from repeated measurements, 
and type B uncertainty was calculated using uncertainties in the purity of the reference 
compound, inaccuracy in the weighing of each component, and the measurement of the 
serum density. Calculated type A and B uncertainties were combined to determine the 
standard uncertainty and multiplied by a coverage factor, k = 2, to determine the expanded 
uncertainty using QCLow, QCMedium, and QCHigh.
In total, 29 structural analogues and other steroid hormones with relative molecular masses 
close to E2 and the IS were tested as potential interferences (Table 1). The absence of a peak 
with the mass transitions of E2 (m/z 271 → 145) or the IS (m/z 276 → 187) at the retention 
time of E2 at 11.3 min confirmed that the structural analogues did not interfere with the 
quantitation of E2. In addition, the QI/CI ratio of E2 was monitored in the 40 single-donor 
samples and compared to the QI/CI ratio of the calibrators. A difference of less than ±20% 
was used to confirm that no interfering compounds were present.31
The effect of different sample matrixes was determined following procedures previously 
described.25 Four sample matrixes (0.9% saline solution, charcoal stripped serum, male 
serum, and female serum) and one set of neat samples in ethanol were evaluated. A 7-point 
calibration curve ranging from 147 to 848 pM (40–231 pg/mL) was prepared in each matrix 
and spiked with 551 pM (150 pg/dL) IS solution. The calibrators in the matrixes were 
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subjected to the sample preparation described above. The MS response (area count ratios of 
analyte to IS) was compared in all four matrixes to the MS response of the neat samples 
prepared in ethanol (matrix-free). The sample matrix effect (ME) was calculated with the 
following equation: ME % = B/A × 100, where B is the area count ratios of E2 to IS 
obtained from samples in matrix, and A is the area count ratios in matrix-free samples.
RESULTS AND DISCUSSION
The trueness and imprecision of an RMP needs to be smaller than that of routine 
measurement procedures to ensure target values assigned have a sufficiently low uncertainty 
so that any uncertainty added by a routine method can then still lead to clinically meaningful 
results. RMPs should have a limit that is half the limit for a routine method for imprecision 
and a limit that is one-third the maximum bias.32,33 The CDC HoSt Program for E2 certifies 
analytical performance criteria for a routine E2 assay with a difference of ±12.5% at 
concentrations <73.4 pmol/L (20.0 pg/mL) and ±2.5 pg at concentrations > 73.4 pmol/L 
(20.0 pg/mL) from the true value and includes a suggested imprecision of 11.3%.15 The 
described cRMP meets the suggested performance criteria for E2 with a bias within ±2.8% 
and imprecision of ≤5.7%. These characteristics are similar to those of established 
RMPs.22–24
A comparison of our cRMP against an established RMP using 40 samples over a 
concentration range of 2.61–1 050 pM (0.71–285 pg/mL) using Deming regression analysis 
with a variance ratio of 1 and t test, α = 0.05 found no statistically significant difference 
(Table 2). The agreement between the candidate and reference measurement procedure did 
not change when the samples were evaluated separately for low (typically found in 
postmenopausal women), medium (typically found in postmenopausal women and men), 
and high (typically found in premenopausal women) E2 concentrations. The mean percent 
bias of the cRMP to the established RMP for the 40 samples was 0.5% (95% CI, 0.1–0.9%; 
SE 0.21%), which is well within the suggested bias criterion of ±2.8%. All measurement 
results obtained with the IRMM serum-based certified reference materials were within 
±0.9% of the assigned certified values for BCR 576, 577, and 578 and showed no significant 
bias when evaluated following the protocol described in NIST Special Publication 82928 
(Table 3). Not only does the cRMP have an overall mean bias within suggested criteria, but 
each evaluated individual sample met this criteria, indicating no relevant sample specific 
bias.
The intra-assay and interassay imprecision was less than 2.7% for all three levels of QC 
material tested (Table 4). The combined or total imprecision was less than 2.4%. Uncertainty 
was assessed at three levels as shown in Table 4 for both type A and type B factors. The 
relative expanded uncertainty was ≤ 4.8% at each level. Type B uncertainty was minimized 
through the use of primary standards with purity >98% and the use of gravimetric 
measurements in place of volumetric measurements in preparation of standards and samples. 
The imprecision and uncertainty were consistent and independent of concentrations of E2 in 
the cRMP, meeting performance goals across concentrations in premenopausal women, men, 
and postmenopausal women serum samples.
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The cRMP provided high levels of accuracy and precision. This was achieved by gravimetric 
measurements, bracketing of calibrators, enhanced chromatographic resolution, and mass 
transitions specific to E2. Volumetric steps were replaced with gravimetric measurements to 
minimize the contributions of imprecision and inaccuracy from pipets and volume changes 
due to changes in temperature.34 Bracketing calibration around the target concentration, a 
common practice for reference methods, further increased precision and accuracy.35,36 
Variability at the extremes of the large dynamic concentration range commonly observed in 
regular calibration curves (2.61-1 100 to pM) was minimized with bracketing into three 
different levels for quantitation. These adjustments were used so that the analyte and IS were 
close in concentration, which reduced the variability of signal intensities and measurement 
imprecision by reducing potential concentration-dependent ion suppression effects that 
would result from significantly different concentrations of IS and analyte entering the mass 
spectrometer.37
The structural analogues and potential interfering compounds of E2 listed in Table 1 either 
did not contain the same mass transitions or were chromatographically separated from E2 
(11.3 min). When an IS-only sample was monitored, no additional peaks were observed in 
the analyte signal, confirming the absence of isotopic interferences from the use of the 
selected internal standard.
The mass transitions used for quantitation by the cRMP were highly specific to E2 and 
included the precursor ion for E2 (271 m/z) as well as a fragment ion (145 m/z). Several LC-
MS/MS methods for E2, as well as the previously described LC-MS/ MS RMP, use dansyl 
chloride as a derivatizing agent to enhance the ionization of E2 in the source and to increase 
the method’s sensitivity. However, with these methods the dansyl fragment ion is used to 
quantitate E2, thereby limiting the specificity of the method. This limitation is overcome in 
our method by measuring E2 without derivatization.
In addition the specificity of the mass transitions to E2 without derivatization for both the QI 
and CI allowed for the use of QI/CI ratios to rule out any potential interferences. For this 
method, the QI/CI ratios in 40 single-donor serum samples were compared to the neat 
calibrators. The mean QI/ CI ratio of 9 replicates of each calibrator was 1.12 (95% CI of 
1.11–1.13) and mean ratio of 40 samples from 2.61 to 1 050 pM was 1.11 (95% CI of 1.11–
1.12). The QI/CI ratios of all 40 serum samples were well within ±20% of the mean QI/CI 
ratio of calibrators, indicating that the cRMP is not affected by interfering compounds.
Chromatographic resolution was important for the cRMP to ensure any potential interfering 
compounds that could be identified by the QI/CI were properly resolved. An example is 
shown in Figure 1, where several additional peaks can be found resolved from the E2 peak at 
11.3 min in the serum sample (Figure 1B) as compared to the neat sample (Figure 1A). In 
example, if the peaks in the 2 min window (9.3–11.3 min) in Figure 1B were not properly 
resolved, the concentration of the serum sample in Figure 1B, with a true E2 concentration 
of 26.5 pM (7.21 pg/mL), would increase by approximately 173% to 72.7 pM (19.8 pg/mL).
A phenyl/hexyl column was used to improve the separation of aromatic compounds with a 9 
min gradient from 48% to 62% of buffer B to further resolve E2. The change in percent 
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buffer B (1.6% per min) is similar to the previously published LC-MS/MS RMP24 (1.4% per 
min) but was accomplished in less than half the time, thus increasing the throughput while 
still achieving the required resolution. This chromatographic approach allowed us to resolve 
several additional peaks that could potentially contribute to inaccurate E2 results.
Maximizing the recovery of E2 during sample preparation is important in ensuring adequate 
signal strength during LC-MS/MS analysis. Low recovery can affect the method’s LOD as 
well as precision if ample analyte and IS are not recovered, especially at the low 
concentrations of E2. The overall extraction efficiency of the procedure was assessed by 
spiking IS prior to sample preparation and injection onto the LC-MS/ MS in duplicate at a 
concentration of 1.02 nM (279 pg/mL) as described previously.38 An extraction recovery of 
90.2% (7.7% CV) was achieved. To enhance ionization and sensitivity of the method 
without a derivatizing agent, 0.2 mM ammonium fluoride was used in the LC buffer to 
promote ionization of E2 under negative ionization mode.39 Sensitivity sufficient for 
assigning target values to sera from men and pre- and postmenopausal women was achieved 
and is the intended use of this method. Through this approach, the limit of detection (LOD) 
(at a signal-to-noise ratio (S/N) of 10) was 2.61 pM (0.71 pg/mL), which is a slight 
improvement over the previously published LC-MS/MS RMP and has additional specificity 
achieved by avoiding dansyl chloride derivatization.
For evaluation of ME, the slope and r2 values were determined for each matrix and the neat 
calibrators as well as the mean ME % for each matrix (Table 5). On the basis of the data 
presented, the sample matrix effect can be evaluated by two separate observations. First, as 
the slopes of all matrixes and matrix free curves are identical, the absence of any significant 
sample ME on quantification can be confirmed. Second, the sample ME % showed either no 
effect or a slight enhancement for the saline and charcoal stripped matrixes evaluated 
(>100%). The serum samples had a ME % of 96.2% and 92.2%, indicating slight ion 
suppression from the matrix, as expected with increased serum volume requirements for 
samples with lower concentrations of E2 such as male samples. However, our evaluations 
have shown no significant effect of this matrix effects on the accuracy and precision of our 
method in both male and female samples.
Sample preparation of the cRMP plays a key role in ensuring that no interferences and no 
significant matrix effects exist. This is achieved in part through the selected conditions used 
during the isolation of the analyte from the matrix. The first LLE isolated the lipids from 
polar compounds. A solution of ethyl acetate/hexane at 3:2, v/v, was selected to maximize 
isolation of the analyte from the matrix. The addition of a basic solution (ammonium 
carbonate buffer, pH 8.2) to the sample extract and the second LLE allowed for the removal 
of acidic impurities, such as fatty acids and phospholipids. These lipids are a source of ion 
suppression and matrix effects, particularly in LC-MS/MS analyses.37 A higher pH for the 
ammonium carbonate buffer would increase the removal of impurities;25 however, the pH of 
8.2 was selected to be two pH units below the pKA of E2 (10.5) to avoid deprotonation and 
subsequent decrease in recovery of E2.40
The cRMP has been automated using the Hamilton Starlet (Reno, NV) equipped with an 
analytical balance. The enhancement to the method doubled the sample throughput 
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compared to the manual sample preparation which helps to meet the increasing demand for 
target value assignments.
CONCLUSION
The described ID LC-MS/MS cRMP for measuring total 17-β estradiol with sufficient 
sensitivity for assigning target values to sera from men, and pre- and postmenopausal 
women, has higher specificity at similar accuracy and precision performance compared to 
existing RMPs. High specificity is needed to ensure accurate target value assignment, 
especially in samples with low E2 concentrations, where small amounts of interfering 
compounds can have a high impact on the measurement result. The cRMP is suitable to 
address the current unmet needs of clinical laboratories, assay manufacturers, and PT 
providers by providing value assignments to serum for calibration and verification of method 
performance as part of the CDC HoSt Program.
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Figure 1. 
Chromatograms of neat and serum sample for E2 (retention time, 11.3 min): (A) neat, E2 
concentration of 20.3 pM (5.52 pg/mL), (B) native serum sample, E2 concentration of 26.5 
pM (7.21 pg/mL) resolved from additional interference peaks.
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Table 1
List of Steroid Hormones Used for Interference Analysis Including the Molecular Weight, Concentration Used 
during Testing, and Source of Material Used
steroid MW (g/mol) concn nM (ng/mL) vendor
4,16-Androstadien-3β-ol 272.43 0.41 (0.11) Steraloids, Inc. (Newport, RI)
5,16-Androstadien-3β-ol 272.43 0.41 (0.11) Steraloids, Inc. (Newport, RI)
Androstenediol 290.44 0.38 (0.11) Steraloids, Inc. (Newport, RI)
Androstenedione 290.44 0.38 (0.11) LGC Standards (Manchester, NH)
16,(5α)-Androsten-3-one 272.43 0.41 (0.11) Steraloids, Inc. (Newport, RI)
2,(5α)-Androsten-17-one 272.43 0.41 (0.11) Steraloids, Inc. (Newport, RI)
Androsterone 290.40 0.38 (0.11) Steraloids, Inc. (Newport, RI)
5α-Cholestane 372.67 0.30 (0.11) Steraloids, Inc. (Newport, RI)
6-Dehydronandrolone 272.38 0.41 (0.11) Steraloids, Inc. (Newport, RI)
Dehydroepiandrosterone (DHEA) 288.42 0.39 (0.11) Cerilliant (Round Rock, TX)
Dehydroepiandrosterone sulfate (DHEAS) 368.49 0.30 (0.11) Cerilliant (Round Rock, TX)
1-Dehydrotestosterone 286.41 0.39 (0.11) Steraloids, Inc. (Newport, RI)
3-Deoxydehydroepiandrosterone (3-deoxy DHEA) 272.43 0.41 (0.11) Steraloids, Inc. (Newport, RI)
17-Desoxyestradiol 256.40 0.43 (0.11) Steraloids, Inc. (Newport, RI)
5a-Dihydrotestosterone (DHT) 290.44 0.38 (0.11) Cerilliant (Round Rock, TX)
Epiandrosterone 290.44 0.38 (0.11) Sigma-Aldrich (St. Louis, MO)
17α-Estradiol (epiestradiol) 272.38 0.41 (0.11) Steraloids, Inc. (Newport, RI)
Epitestosterone 288.42 0.39 (0.11) Cerilliant (Round Rock, TX)
1,3,5(10)-Estratrien-16β, 17β-epoxy-3-ol 272.38 0.41 (0.11) Steraloids, Inc. (Newport, RI)
5(10)-Estren-3,17-dione 272.40 0.41 (0.11) Steraloids, Inc. (Newport, RI)
Estriol 288.38 0.39 (0.11) Cerilliant (Round Rock, TX)
Estrone 270.37 0.41 (0.11) Cerilliant (Round Rock, TX)
17α-Ethynylestradiol 296.40 0.37 (0.11) Cerilliant (Round Rock, TX)
Etiocholanolone 290.40 0.38 (0.11) Cerilliant (Round Rock, TX)
2-Methoxyestradiol 302.41 0.37 (0.11) Steraloids, Inc. (Newport, RI)
17α-Methyl-5α-androstane-3α,17β-diol 306.49 0.36 (0.11) Cerilliant (Round Rock, TX)
17-α Methyltestosterone 302.46 0.37 (0.11) Cerilliant (Round Rock, TX)
19-Norethindrone 298.42 0.37 (0.11) Steraloids, Inc. (Newport, RI)
D(−)-Norgestrel 312.45 0.36 (0.11) Sigma-Aldrich (St. Louis, MO)
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Table 2
Method Comparison to a Recognized RMP Using 40 Single-Donor Samples and Deming Regression Analysis
sample group n
range
pM
(pg/mL)
slope (95% CI)
[SE, p]a
intercept (95% CI)
[SE, p]a
2.61–1 050 1.00 0.02
all 40 (0.71–285) (0.997–1.008) (−0.02–0.05)
[0.003, 0.363] [0.018, 0.311]
high (>257 pM)b 277–1 050 1.00 1.38
14 (75.4–285) (0.978–1.011) (−1.17–3.93)
[0.007, 0.499] [1.170, 0.260]
medium (36.7–257 pM)c 43.7–203 0.99 0.38
15 (11.9–55.3) (0.962–1.010) (−0.06–0.83)
[0.011, 0.234] [0.206, 0.085]
low (<36.7 pM)d 2.61–26.5 0.99 0.03
11 (0.71–7.21) (0.979–1.008) (−0.02–0.08)
[0.006, 0.365] [0.021, 0.197]
aSE = standard error.
bConcentrations typically found in premenopausal females.
cConcentrations typically found in males and postmenopausal females.
dConcentrations typically found in postmenopausal females.
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Table 3
Bias Assessment Using JCTLM-Recognized Reference Materials
IRMM BCR material reference target value, pM (pg/mL) bias, % (95% CI)
BCR 576 114 (31.1) 0.3 (0.2–0.5)a
BCR 577 690 (188)
−0.3 (−2.4–1.8)a
BCR 578 140 (365)
−0.9 (−4.0–2.2)a
aNo significant bias when evaluated following the protocol described in NIST Special Publication 829.26
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Table 4
Inter-, Intra-, and Total Assay Imprecision and Estimation of Expanded Uncertainties of cRMP Measurements 
of Estradiol in Serum at Three Concentrationsa
QCHigh QCMedium QCLow
concn pM (pg/mL) 455 (124) 147 (40.0) 19.2 (5.23)
interassay CV, % 2.7 2.4 2.3
intra-assay CV, % 1.3 1.3 1.1
total CV, % 2.4 2.0 2.4
type A (pM) 10.92 2.94 0.38
type B (pM) 0.01 0.01 0.01
combined standard uncertainty 10.92 2.94 0.38
coverage factor 2 2 2
expanded uncertainty (95% confidence interval) 21.8 5.88 0.77
relative expanded uncertainty (%) 4.8 4.0 4.0
aSamples were measured in triplicate over 5 days.
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